ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KERX Keryx Biopharmaceuticals, Inc. (delisted)

3.36
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Keryx Biopharmaceuticals, Inc. (delisted) NASDAQ:KERX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.36 3.10 3.35 0 01:00:00

Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming October 3rd Deadline in the Class Action Law...

22/09/2016 6:07pm

Business Wire


Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.

Investors with losses of $50,000 or more are encouraged to contact the firm to discuss their legal rights.

Law Offices of Howard G. Smith reminds investors of the upcoming October 3, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the “Class”) of investors who purchased or otherwise acquired Keryx Pharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX) securities between September 2, 2013, and August 1, 2016, inclusive (the “Class Period”). Keryx investors have October 3, 2016 to file a lead plaintiff motion.

The complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and/or failed to disclose: (1) that the Company was experiencing production-related difficulties in converting API to finished drug product; (2) that the issue was resulting in decreased production yields of finished drug product; (3) that, as a result, the Company would, and did exhaust its reserve of finished drug product; and (4) that, as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you purchased Keryx shares, you may move the Court no later than October 3, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com

1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart

Your Recent History

Delayed Upgrade Clock